Is now at
Argyll Park, Dixon, California


Post-ischemic treatment with TC decreased cerebral infarct size and edema.

Cell-culture research of embryonic rat cortical neurons and glia exposed to OGD/R to simulate ischemic insult verified some of the results of the in vivo studies and contributed to help expand understanding about cellular ramifications of ischemia and TC treatment. In the cultures, TC decreased neuronal damage, intracellular oxidative stress, and mitochondrial depolarization pursuing OGD/R, and the effects had been reversed by AM630 but not by a CB1R antagonist, AM251. Western blot analysis demonstrated that TC improved the phosphorylation of AMP proteins kinase and CREB, while selective AMPK and CREB inhibitors blocked TC's neuroprotection. Additional findings indicated that the anti-ischemic aftereffect of TC was not mediated by NMDA receptor antagonism or antioxidant activity.Based on the AHA, ‘cardiovascular disease and stroke will be the No. 1 causes of loss of life and disability among people who have type II diabetes. In fact, at least 65 % of individuals with diabetes die from some type of cardiovascular disease or stroke.’ It’s hard to disregard so many alarming information, yet it appears that’s exactly what the majority of our country does while at exactly the same time producing Big Pharma extremely rich.

ChemoCentryx CCX140 Stage II research on type 2 diabetes meets primary endpoint ChemoCentryx, Inc. Announced that CCX140 today, the business’s novel, orally energetic CCR2 antagonist successfully met its principal endpoint of security and tolerability and demonstrated medical efficacy in a Phase II study in sufferers with type 2 diabetes on stable doses of metformin.